Mesoblast Limited (MESO) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.56: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as... Read more
Sell if holding. Engine safety override at $15.56: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Score 4.3/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, news boost earnings 0.60, earnings proximity 119d clear, semi cycle peak clear). Fails on clean insider activity. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.56: Quality below floor (2.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 6.3:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality; Rich valuation; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $14.52. Score 4.3/10, moderate confidence.
Take-profit target: $29.75 (+91.2% upside). Prior stop was $14.52. Stop-loss: $14.52.
Quality below floor (2.2 < 4.0); Value-trap signals (2/5): Margin compression (op margin -3.1%), Material insider selling (11 sells, 0.16% of cap).
Mesoblast Limited trades at a P/E of N/A (forward -222.1). TrendMatrix value score: 0.0/10. Verdict: Sell.
10 analysts cover MESO with a consensus score of 4.1/5. Average price target: $35.
What does Mesoblast Limited do?Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in...
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.